MACROGENICS INC Form SC 13G February 14, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

MACROGENICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

556099109

(CUSIP Number)

December 31, 2013

(Date of Event That Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- o Rule 13d-1(c)
- x Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

(1)	Names of Reporting Persons. Alta BioPharma Partners III, L.P.					
(2)	(2) Check the Appropriate Box if a Member of a Group (a) 0 (b) x					
(3)	SEC Use Only					
(4)	(4) Citizenship or Place of Organization Delaware					
Number of	(5)	Sole Voting Power 1,844,208 (a)				
Shares Beneficially Owned by	(6)	Shared Voting Power -0-				
Each Reporting Person With	(7)	Sole Dispositive Power 1,844,208 (a)				
Terson with	(8)	Shared Dispositive Power -0-				
(9)	Aggregate Amount Beneficially Own 1,844,208(a)	ned by Each Reporting Person				
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares					
(11)	Percent of Class Represented by Am 7.37% (b)	Percent of Class Represented by Amount in Row (9) 7.37% (b)				
(12)	Type of Reporting Person PN					

⁽a) Alta BioPharma Partners III, L.P. (ABPIII) has sole voting and dispositive control over 1,844,208 shares of common stock (Common Stock) of MacroGenics, Inc. (the Issuer), except that Alta BioPharma Management III, LLC (ABMIII), the general partner of ABPIII, and Farah Champsi (Champsi), and Edward Hurwitz (Hurwitz), and Edward Penhoet (Penhoet), directors of ABMPIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about ABPIII is set forth in Attachment A hereto.

⁽b) The percentage set forth in row (11) is based on an aggregate of 25,020,288 shares of Common Stock outstanding as of October 31, 2013 as reported in the Issuer s 10-Q filing for the quarter ended September 30, 2013.

(1)	Names of Reporting Persons. Alta BioPharma Partners III GmbH & Co. Beteiligungs KG				
(2)	(2) Check the Appropriate Box if a Member of a Group				
	(a)	0			
	(b)	X			
(3)	SEC Use Only				
(4)	Citizenship or Place of Organization Germany				
Number of	(5)		Sole Voting Power 123,854 (c)		
Shares Beneficially Owned by	(6)		Shared Voting Power -0-		
Each Reporting Person With	(7)		Sole Dispositive Power 123,854 (c)		
	(8)		Shared Dispositive Power -0-		
(9)	Aggregate Amount Beneficial 123,854 (c)	ly Owned by Each Reporting	ng Person		
(10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares				
(11)	Percent of Class Represented by Amount in Row (9) 0.50% (b)				
(12)	Type of Reporting Person PN				

⁽c) Alta BioPharma Partners III GmbH & Co. Beteiligungs KG (ABPIIIKG) has sole voting and dispositive control over 123,854 shares of Common Stock, except that ABMIII, the managing limited partner of ABPIIIKG, Champsi, Penhoet, and Hurwitz, directors of ABMPIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about ABPIIIKG is set forth in Attachment A hereto.

(1)		Names of Reporting Persons.				
		Alta BioPharma Management III, LLC				
(2) Check the Appropriate Box if a Member of a Group (a) 0 (b) x						
(3)		SEC Use Only Citizenship or Place of Organization Delaware				
(4)						
Number of		(5)		Sole Voting Power -0-		
Shares Beneficially Owned by		(6)		Shared Voting Power 1,968,062 (d)		
Each Reporting Person With		(7)		Sole Dispositive Power -0-		
		(8)		Shared Dispositive Power 1,968,062 (d)		
(9)		Aggregate Amount Beneficially Owned by Each Reporting Person 1,968,062 (d)				
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares						
(11))	Percent of Class Represented by Amount in Row (9) 7.87%(b)				
(12))	Type of Reporting Person OO				

⁽d) ABMIII shares voting and dispositive power over the 1,844,208 shares of Common Stock beneficially owned by ABPIII and the 123,854 shares of Common Stock beneficially owned by ABPIIIKG. Additional information about ABMIII is set forth in Attachment A hereto.

(1)	Names of Reporting Persons.	Names of Reporting Persons.			
	Alta Embarcadero BioPharma Partners	III, LLC			
(2)	Check the Appropriate Box if a Member (a) o (b) x	r of a Group			
(3)	SEC Use Only				
(4)	Citizenship or Place of Organization California				
Number of	(5)	Sole Voting Power 45,447 (e)			
Shares Beneficially Owned by	(6)	Shared Voting Power -0-			
Each Reporting Person With	(7)	Sole Dispositive Power 45,447 (e)			
Terson with	(8)	Shared Dispositive Power -0-			
(9)	Aggregate Amount Beneficially Owned 45,447 (e)	by Each Reporting Person			
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares					
(11)	Percent of Class Represented by Amour 0.18% (b)	Percent of Class Represented by Amount in Row (9) 0.18% (b)			
(12)	Type of Reporting Person OO				

⁽e) Alta Embarcadero BioPharma Partners III, LLC (AEBPIII) has sole voting and dispositive control over 45,447 shares of Common Stock, except that Champsi, Penhoet, and Hurwitz, managing directors of AEBPIII, may be deemed to share the right to direct the voting and dispositive control over such stock. Additional information about AEBPIII is set forth in Attachment A hereto.

(1)	Names of Reporting Persons.				
	Farah Champsi				
(2) Check the Appropriate Box if a Member of a Group (a) o (b) x					
(3)	SEC Use Only	SEC Use Only			
(4) Citizenship or Place of Organization United States					
Number of	(5)		Sole Voting Power -0-		
Shares Beneficially Owned by	(6)		Shared Voting Power 2,013,509 (h)		
Each Reporting Person With	(7)		Sole Dispositive Power -0-		
	(8)		Shared Dispositive Power 2,013,509 (h)		
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person 2,013,509 (h)				
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares					
(11)	(11) Percent of Class Represented by Amount in Row (9) 8.05% (b)				
(12)	Type of Reporting Perso IN	on			

⁽h) Champsi shares voting and dispositive control over the 1,844,208 shares of common stock beneficially owned by ABPIII, the 123,854 shares of Common Stock beneficially owned by ABPIIIKG, and the 45,447 shares of Common Stock beneficially owned by ABPIII. Additional information about Champsi is set forth in Attachment A hereto.

(1)	Names of Reporting Persons.				
	Edward Penhoet				
(2) Check the Appropriate Box if a Member of a Group (a) 0 (b) x					
(3)	SEC Use Only				
(4)	(4) Citizenship or Place of Organization United States				
Number of	(5)		Sole Voting Power -0-		
Shares Beneficially Owned by	(6)		Shared Voting Power 2,013,509 (i)		
Each Reporting Person With	(7)		Sole Dispositive Power -0-		
	(8)	Shared Dispositive 2,013,509 (i)			
(9)	Aggregate Amount Beneficially Owned by Each Reporting Person 2,013,509 (i)				
(10)	Check if the Aggregate Amo	ount in Row (9) Excludes Cer	rtain Shares		
(11)					
(12)	Type of Reporting Person IN				

⁽i) Penhoet shares voting and dispositive control over the 1,844,208 shares of common stock beneficially owned by ABPIII, the 123,854 shares of Common Stock beneficially owned by ABPIIIKG, and the 45,447 shares of Common Stock beneficially owned by ABPIII. Additional information about Penhoet is set forth in Attachment A hereto.

(1)	Names of Reporting Persons.				
	Edward Hurwitz				
(2)	Check the Appropriate Box if (a) (b)	a Member of a Group o x			
(3)	SEC Use Only				
(4)	Citizenship or Place of Organi United States	zation			
Number of	(5)		Sole Voting Power -0-		
Shares Beneficially Owned by	(6)		Shared Voting Power 2,013,509 (j)		
Each Reporting Person With	(7)		Sole Dispositive Power -0-		
Torson with			Shared Dispositive Power 2,013,509 (j)		
(9)	Aggregate Amount Beneficial 2,013,509 (j)	ly Owned by Each Reporting	ng Person		
(10)	(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares				
(11)	Percent of Class Represented by Amount in Row (9) 8.05% (b)				
(12) Type of Reporting Person IN					

⁽j) Hurwitz shares voting and dispositive control over the 1,844,208 shares of common stock beneficially owned by ABPIII, the 123,854 shares of Common Stock beneficially owned by ABPIIIKG, and the 45,447 shares of Common Stock beneficially owned by ABPIII. Additional information about Hurwitz is set forth in Attachment A hereto.

CUSIP No. 556099109 Item 1. Name of Issuer: MacroGenics, Inc. (Issuer) (a) (b) Address of Issuer s Principal Executive Offices: 9640 Medical Center Drive Rockville, Maryland 20850 Item 2. Name of Person Filing: (a) Alta BioPharma Partners III, L.P. (ABPIII) Alta BioPharma Management III, LLC (ABMIII) Alta BioPharma Partners III GmbH & Co. Beteiligungs KG (ABPIIIKG) Alta Embarcadero BioPharma Partners III, LLC (AEBPIII) Farah Champsi (FC) Edward Penhoet (EP) Edward Hurwitz (EH) Address of Principal Business Office: (b) One Embarcadero Center, Suite 3700 San Francisco, CA 94111

(c) Citizenship/Place of Organization: Entities: ABPIII Delaware ABMIII Delaware ABPIIIKG Germany AEBPIII California Individuals: FC United States EP United States ЕН United States Title of Class of Securities: (d) Common Stock CUSIP Number: 556099109 (e) Item 3. Not applicable. 9

CUSIP No. 556099109

Item 4 Ownership.

Please see Attachment A

10

		ABPIII	ABMIII	ABPIIIKG	AEBPIII
(a)	Beneficial Ownership	1,844,208	1,968,062	123,854	45,447
(b)	Percentage of Class	7.37%	7.87%	0.50%	0.189
(c)	Sole Voting Power	1,844,208	-0-	123,854	45,447
	Shared Voting Power	-0-	1,968,062	-0-	-0-
	Sole Dispositive Power	1,844,208	-0-	123,854	45,447
	Shared Dispositive Power	-0-	1,968,062	-0-	-0-
		FC	EP	ЕН	
(a)	Beneficial Ownership	2,013,509	2,013,509	2,013,509	
(b)	Percentage of Class	8.05%	8.05%	8.05%	
(c)	Sole Voting Power	-0-	-0-	-0-	
	Shared Voting Power	2,013,509	2,013,509	2,013,509	
	Sole Dispositive Power	-0-	-0-	-0-	
	Shared Dispositive Power	2,013,509	2,013,509	2,013,509	

Item 5.	Ownership of Five Percent or Less of a Class
	iled to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than curities, check the following o.
Item 6.	Ownership of More than Five Percent on Behalf of Another Person
Not applicable.	
Item 7. Parent Holding Compan	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the y.
Not applicable.	
Item 8.	Identification and Classification of Members of the Group
No reporting person is a m	nember of a group as defined in Section 240.13d-1(b)(1)(ii)(H) of the Act.
Item 9.	Notice of Dissolution of Group
Not applicable.	
Item 10.	Certification
Not applicable.	

EXHIBITS

A: Joint Filing Statement

11

CUSIP No.	556099109
-----------	-----------

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2014

ALTA BIOPHARMA PARTNERS III, L.P.

By: Alta BioPharma Management III, LLC

ALTA BIOPHARMA MANAGEMENT III, LLC

By: /s/ Farah Champsi

Farah Champsi, Director

By: /s/ Farah Champsi

Farah Champsi, Director

ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC

ALTA BIOPHARMA PARTNERS III GMBH &CO. **BETEILIGUNGS KG**

By: Alta BioPharma Management III, LLC

/s/ Farah Champsi By:

Farah Champsi, Manager

/s/ Farah Champsi Farah Champsi, Director

/s/ Farah Champsi Farah Champsi

/s/ Edward Hurwitz **Edward Hurwitz**

/s/ Edward Penhoet **Edward Penhoet**

CUSIP No. 556099109

EXHIBIT A

AGREEMENT OF JOINT FILING

We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of us.

Date: February 14, 2014

ALTA BIOPHARMA PARTNERS III, L.P.

By: Alta BioPharma Management III, LLC

ALTA BIOPHARMA MANAGEMENT III, LLC

By: /s/ Farah Champsi

Farah Champsi, Director

By: /s/ Farah Champsi

Farah Champsi, Director

ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC

ALTA BIOPHARMA PARTNERS III GMBH &CO.

BETEILIGUNGS KG

By: Alta BioPharma Management III, LLC

By: /s/ Farah Champsi

Farah Champsi, Manager

/s/ Farah Champsi

Farah Champsi, Director

/s/ Farah Champsi Farah Champsi /s/ Edward Hurwitz

Edward Hurwitz

/s/ Edward Penhoet Edward Penhoet

13

CI	IS	ID.	Nο	5560	7991	09

Attachment A

Alta BioPharma Partners III, L.P. beneficially owns 1,844,208 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.

Alta BioPharma Partners III GmbH & Co. Beteiligungs KG beneficially owns 123,854 shares of Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.

Alta Embarcadero BioPharma Partners III, LLC beneficially owns 45,447 shares Common Stock and exercises sole voting and dispositive control over such shares, except to the extent set forth below.

Alta BioPharma Management III, LLC is the general partner of Alta BioPharma Partners III, L.P. and the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG and may be deemed to share the right to direct the voting and dispositive control over the shares held by such fund.

Ms. Farah Champsi is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC. She may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.

Mr. Edward Hurwitz is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC. He may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.

Mr. Edward Penhoet is a director of Alta BioPharma Management III, LLC, and a manager of Alta Embarcadero BioPharma Partners III, LLC. He may be deemed to share the right to direct the voting and dispositive control over the shares held by such funds.